GLP-1 receptor agonists (including semaglutide) and DPP-4 inhibitors significantly reduced kidney cyst formation in a zebrafish model of nephronophthisis, the leading genetic cause of kidney failure in children.
Dose-dependent cyst reduction with semaglutideThe GLP-1 agonist semaglutide and DPP-4 inhibitors all significantly reduced kidney cyst formation in a zebrafish model of the leading genetic cause of childhood kidney failure.
What the researchers found
A systematic drug repurposing screen in nphp1/nphp4-depleted zebrafish identified GLP-1 signaling as a novel therapeutic target for nephronophthisis. DPP-4 inhibitors (omarigliptin and linagliptin) and the GLP-1 receptor agonist semaglutide significantly reduced cystogenesis in a dose-dependent manner. Genetic analysis confirmed GLP-1 receptors (gcgra and gcgrb) are important for pronephros integrity. Transcriptomics identified adenosine receptor A2ab (adora2ab) as a key downstream effector regulating ciliary morphology. Nphp1/nphp4 double mutant zebrafish showed compensatory upregulation of GLP-1 receptor genes, and disrupting this compensation enhanced cyst formation.
Why it matters
Nephronophthisis has no treatment — affected children inevitably progress to kidney failure requiring dialysis or transplant. The discovery that already-approved, widely-used GLP-1 medications could potentially treat this condition is a major breakthrough. Drug repurposing from FDA-approved medications could dramatically shorten the path from discovery to clinical use, potentially helping patients within years rather than decades.
How the study worked
Researchers developed a zebrafish model of nephronophthisis by simultaneously depleting nphp1 and nphp4 genes, reproducing glomerular cyst formation. They performed a systematic drug repurposing screen testing FDA-approved medications. Hits were validated with dose-response studies. Genetic analysis using morpholinos and mutants dissected the signaling pathway. Transcriptomic profiling identified downstream effectors. GLP-1 receptor depletion and adenylate cyclase inhibition experiments confirmed the signaling cascade.
What this study cannot tell us
Zebrafish kidney biology differs significantly from human kidneys, and findings may not translate directly. The pronephros (zebrafish kidney) is structurally simpler than the mammalian metanephros. No mammalian validation was performed. The screen identified pathway-level effects but clinical dosing for this indication is unknown. The compensatory GLP-1 receptor upregulation seen in mutant zebrafish may or may not occur in human NPH patients.
How to read the evidence
This is a preclinical study using a zebrafish disease model with systematic drug screening, genetic validation, and transcriptomic analysis. The methodology is rigorous and the mechanistic dissection is thorough, but findings are limited to zebrafish and require mammalian validation before clinical translation.
When this study was published
Published in 2025, this is a very recent discovery that could open a new therapeutic avenue for an untreatable childhood kidney disease using already-approved medications.
The bigger picture
This study reveals an entirely unexpected role for GLP-1 signaling in kidney cyst biology and ciliary function. As GLP-1 agonists are already showing kidney-protective effects in diabetes trials, this finding suggests their renal benefits may extend to completely different kidney diseases driven by ciliary defects. It also adds to the remarkable expansion of GLP-1 drug applications beyond their original metabolic indications.
Questions still open
- Will GLP-1 agonists reduce cystogenesis in mammalian models of nephronophthisis or polycystic kidney disease?
- Could children with nephronophthisis benefit from early treatment with GLP-1 agonists or DPP-4 inhibitors to slow disease progression?
- Does the GLP-1 → adenosine receptor → ciliary morphology pathway also operate in human kidney cells?
Common questions
Could diabetes drugs help treat a childhood kidney disease?
What is nephronophthisis and why is this finding important?
Read the original research
Targeting GLP-1 Signaling Ameliorates Cystogenesis in a Zebrafish Model of Nephronophthisis.
International journal of molecular sciences, 26(15)
Citation
Eckert, Priska; Nöller, Maike; Müller, Merle; Haas, Rebecca; Ruf, Johannes; Franz, Henriette; Moos, Katharina; Yu, Jia-Ao; Zhao, Dongfang; Xie, Wanqiu; Boerries, Melanie; Walz, Gerd; Yakulov, Toma A. (2025). Targeting GLP-1 Signaling Ameliorates Cystogenesis in a Zebrafish Model of Nephronophthisis.. International journal of molecular sciences, 26(15). https://doi.org/10.3390/ijms26157366